All companies
Visit website
FISHER WALLACE LABORATORIES
OperatingFisher Wallace Laboratories, Inc.
Healthcare · Founded 2019
Medical Devices for Mood and Sleep
Post-money valuation ⓘ
$100.8M
As of Aug 2023 · from Reg A Offering (2023) · pre-money + amount raised, not a traded price
Total raised
$11,017,469
Across 18 rounds since 2019
Latest share price
$10.67
Reg CF Offering (2026-04-17) offering price
Financials
FY2017–FY2025 · from SEC filings · hover any figure for its source$4.7M
$200K
2018
$3.9M
−$543K
2019
$4.3M
−$1.8M
2020
$4.2M
−$3.3M
2021
$4.7M
−$7.1M
2022
$4.7M
−$7.1M
2023
$47K
−$1.6M
2024
$34K
−$1.4M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Metric
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$4,653,739
$4,717,684
$3,864,706
$4,250,866
$4,230,290
$4,739,387
$4,739,387
$47,412
$34,261
Cost of goods sold
$1,209,467
$1,082,135
$947,495
$970,761
$623,703
$1,096,113
$1,096,113
$3,012
$5,049
Gross margin
74%
77%
75%
77%
85%
77%
77%
94%
85%
Net income
$414,419
$200,325
-$543,056
-$1,823,732
-$3,262,291
-$7,073,744
-$7,073,744
-$1,579,900
-$1,447,538
Taxes paid
$0
$0
$0
$1,597
$250
$0
$0
$0
$0
Balance sheet
Cash
$333,608
$159,577
$339,584
$695,749
$1,929,380
$128,229
$128,229
$41,626
$48,142
Accounts receivable
$0
$6,658
$30,560
$2,302
$0
$0
$0
$0
$0
Total assets
$341,987
$186,410
$390,878
$853,359
$1,999,403
$439,495
$439,495
$154,382
$144,634
Short-term debt
$556,805
$328,510
$0
$1,094,023
$966,198
$0
$427,470
$596,721
$591,311
Long-term debt
$126,525
$0
$625,525
$620,416
$576,525
$0
$1,083,664
$925,582
$693,612
Total liabilities
$683,330
$328,510
$1,227,009
$1,714,439
$1,542,723
$0
$1,511,134
$1,522,303
$1,284,923
Other
Headcount
—
8
8
6
12
12
3
2
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$16.1M
post-money
$44.7M
post-money
$81.3M
post-money
$81.6M
post-money
$82.6M
post-money
$100.8M
post-money
$100.3M
post-money
Fundraising history
Raised $0 / $4.4M
Raised $130.1K / $2.6M
Raised $195.5K / $2.6MInvestors 158
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 7 of 7 annual reports (FY2019–FY2025)
2,776 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 86 filings on EDGARSource: ManualCIK 0001787792Share price $10.67
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.